Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion type Assertion NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_head.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion description "[In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_provenance.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion evidence source_evidence_literature NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_provenance.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion SIO_000772 23537295 NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_provenance.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion wasDerivedFrom befree-20150227 NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_provenance.
- NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_assertion wasGeneratedBy ECO_0000203 NP635860.RAS44td3B6f6xD8L5xy9CRKb8fYbXAshPMS15eBFQ6xxc130_provenance.